Public Companies
Irwin Naturals Mental Health Clinics to Enter Pacific Northwest
The company agreed to acquire a clinic in Washington.
The post Irwin Naturals Mental Health Clinics to Enter Pacific Northwest appeared first on Green…
Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) will expand its chain of psychedelics mental health clinics into the Pacific Northwest. The company reached a binding, arm’s length agreement to acquire the assets of Tri-Cities Infusion & Wellness Clinic PLLC, which is located in Kennewick, Washington.
The acquisition is an all-stock deal, but the total consideration will not be released until close.
This will be the first facility in Washington for Irwin Naturals Emergence and the 17th facility the chain has signed on or acquired across eight different states.
“We believe this type of treatment has the capacity to change the way we care for mental health in this country,” Klee Irwin, CEO of Irwin Naturals, said in a news release. “We’ve sought to move to the front of this market by moving fast while also being incredibly selective.”
Tyler Thornock and Ben Clark are the co-owners of the clinic, which opened in April 2019. Both are certified registered nurses with special training for anesthesia.
The clinic offers ketamine infusion, which has been used to treat a variety of mood disorders. It also offers nutrient IV infusions, aesthetic procedures, and regenerative treatments such as platelet-rich plasma injections.
The chain, Irwin Naturals Emergence, previously announced agreements with a total of 16 clinics located in seven different states. Last month, it announced an acquisition agreement with a clinic in Idaho.
The post Irwin Naturals Mental Health Clinics to Enter Pacific Northwest appeared first on Green Market Report.
ketamine psychedelics cse otc deal irwin naturals
-
Psychedelics1 week agoCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week agoGoing concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week agoAre Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week agoOptimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week agoAtai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week agoPsyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week agoClearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics1 week agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product